0 items - $0.00 0

Author page: admin

Survey: MS Patients Using Cannabis Medicinally

A survey of more than 1,000 people with multiple sclerosis has found extensive use of complementary and alternative medicine – including the use of cannabis. Researchers at Oregon Health & Science University conducted the survey of MS patients in Oregon and Southwest Washington in 2018, with the results published in the journal Multiple Sclerosis and Related Disorders. Around 30% reported they had…

Continue

CBD for Multiple Sclerosis patients: a powerhouse duo for treating multiple sclerosis

Multiple sclerosis, or MS, is a disease in which a person’s immune system attacks healthy tissues within the central nervous system. This results in a disruption of signals between the brain and the rest of the body, typically causing the person to experience balance and coordination issues, vision problems, fatigue, and cognitive troubles related to memory and concentration. In total,…

Continue

#CMSC2018 – Pharmacist Discusses Advances, Challenges in Cannabinoids Research to Treat MS

Several studies have demonstrated the therapeutic potential of cannabis and its derivate products to manage the symptoms of multiple sclerosis (MS) and other neurodegenerative diseases. But there is still much to be done to enhance their use and accessibility to patients who may benefit from these therapies, according to a recent presentation by Matthew Makelky, PharmD. Makelky, a researcher at the University of…

Continue

Cannabis and Multiple Sclerosis— ew directions cannabis research may help to achieve the goal

The cannabis plant contains up to 110 cannabinoids, though Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been the primary focus of medical investigation. THC has psychoactive effects, such as cognitive impairments, psychosis, dysphoria, and anxiety, whereas CBD is non-intoxicating and has anti-inflammatory, analgesic, and antipsychotic properties, and can counter several unwanted side effects of THC. A significant number of people with…

Continue

Cannabidiol to Improve Mobility in People with Multiple Sclerosis

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that affects an estimated 2.3 million people worldwide (1). The symptoms of MS are highly varied but frequently include pain, muscle spasticity, fatigue, inflammation, and depression. These symptoms often lead to reduced physical activity, negatively impact functional mobility, and have a detrimental impact on patients’ quality of…

Continue

How CBD Reduces Multiple Sclerosis Symptoms Has Now Been Revealed

Multiple Sclerosis (MS) is a chronic, sometimes debilitating, autoimmune disease which affects the brain and spinal cord. Symptoms, and the severity of those symptoms, can vary dramatically over time with many sufferers reporting symptoms worsening steadily over time, or going through periods of relapse and remission where symptoms come and go. The disease is most commonly characterized by issues with mobility, ranging…

Continue

CBD Oil for MS

Multiple Sclerosis is one of those conditions that most of us have heard of, but also seem to know very little about. Often shortened to MS, multiple sclerosis is a degenerative disease that affects movement, senses, and cognitive ability. An increased interest in CBD has led many people to wonder whether CBD oil for MS could prove to be an effective form…

Continue

Harvest One Plans Online Sales of Medical Cannabis for Canadians With MS

United Greeneries plans to launch online retail sales of medical cannabis in February for Canadians covered by the Access to Cannabis for Medical Purposes Regulations — a program for which certain multiple sclerosis (MS) patients may be eligible. United Greeneries, a unit of Harvest One Cannabis, an umbrella company that also owns Switzerland’s Satipharm, has a medicinal cannabis cultivation and sales license. That allows Harvest One to…

Continue

Holland Approves Clinical Trial Plans for AXIM’s Cannabis-based Gum for MS Pain and Spasticity

Dutch regulators have signed off on AXIM Biotechnologies’ clinical trial plans for a chewing gum that offers controlled release of cannabinoids to treat multiple sclerosis patients’ pain and spasticity. The Dutch Medicines Evaluation Board’s sign-off on MedChew Rx means AXIM can start trials. A leader in cannabinoid research, New York-based AXIM is developing 16 cannabinoid-based pharmaceutical, nutrition and cosmetic products for conditions that include MS, irritable…

Continue

Multiple Sclerosis NZ Review of medicinal cannabis research

Review of Current Research Regarding the Use of Medicinal Cannabis for MS And MND Symptom Management A report for Multiple Sclerosis New Zealand and Motor Neurone Disease New Zealand December 2017, by Kerry Walker, MSc. Executive Summary With the increasing interest in Medicinal Cannabis for managing pain and spasticity in MS and other chronic conditions Multiple Sclerosis NZ and Motor…

Continue

PO Box 2711Pismo Beach, CA 93448

Sign up for email

Copyright ® 2020 - MC4MS Website - All rights reserved. Created and powered by MACE Media Group.